Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 2/20 | 0.49 |
| ▸ | CA1 | P00915 | 2/20 | 0.49 |
| ▸ | CA2 | P00918 | 2/20 | 0.49 |
| ▸ | CA7 | P43166 | 2/20 | 0.49 |
| ▸ | CA9 | Q16790 | 2/20 | 0.49 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.49 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 2/20 | 0.47 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.45 |
| ▸ | ESR1 | P03372 | 2/20 | 0.45 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 3/20 | 0.45 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16533471 | 0.85 | NOTUM (0.50) | CA12CA1CA2CA7CA9 | |
| SCHEMBL2617365 | 0.83 | RORC (0.53) | CA12CA1CA2CA7CA9 | |
| SCHEMBL18130284 | 0.82 | ALDH1A1 (0.43) | CA12CA1CA2CA7CA9 | |
| SCHEMBL670686 | 0.82 | HSD17B2 (0.65) | CA12CA1CA2CA7CA9 | |
| SCHEMBL18130281 | 0.81 | ALDH1A1 (0.43) | CA12CA1CA2CA7CA9 | |
| SCHEMBL2543514 | 0.80 | KMT2A (0.51) | CA12CA1CA2CA7CA9 | |
| SCHEMBL8154363 | 0.80 | PDE4B (0.50) | ALDH1A1CYP1A2CYP3A4KDM4EKMT2A | |
| SCHEMBL20021947 | 0.80 | PDE4B (0.53) | ALDH1A1KMT2APOLB | |
| SCHEMBL31535406 | 0.80 | PDE4B (0.50) | ALDH1A1CYP1A2CYP3A4KDM4EKMT2A | |
| SCHEMBL6799389 | 0.80 | HSD17B2 (0.58) | HSD17B2ALOX15RAB9ASMN1; SMN2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2563783-B1 | 3-(4-((1H-IMIDAZOL-1-YL)METHYL)PHENYL)-5-ARYL-1,2,4-OXADIAZOLE DERIVATIVES AS SPHINGOSINE-1 PHOSPHATE RECEPTORS MODULATORS | ALLERGAN INC (US) | 2014-07-23 | — | — | EP | disclosed |
| US-8440698-B2 | 3-(4-((1H-imidazol-1-yl)methyl)phenyl)-5-aryl-1,2,4-oxadiazole derivatives as sphingosine-1 phosphate receptors modulators | ALLERGAN, INC. (US) | 2013-05-14 | — | — | US | disclosed |
| EP-2563783-A1 | 3-(4-((1H-IMIDAZOL-1-YL)METHYL)PHENYL)-5-ARYL-1,2,4-OXADIAZOLE DERIVATIVES AS SPHINGOSINE-1 PHOSPHATE RECEPTORS MODULATORS | Allergan, Inc. (US) | 2013-03-06 | — | — | EP | disclosed |
| US-20120302606-A1 | 3-(4-((1H-IMIDAZOL-1-YL)METHYL)PHENYL)-5-ARYL-1,2,4-OXADIAZOLE DERIVATIVES AS SPHINGOSINE-1 PHOSPHATE RECEPTORS MODULATORS | ALLERGAN, INC. (US) | 2012-11-29 | — | — | US | disclosed |
| US-8318783-B2 | 3-(4-((1H-imidazol-1-yl)methyl)phenyl)-5-aryl-1,2,4-oxadiazole derivatives as sphingosine-1 phosphate receptors modulators | ALLERGAN, INC. (US) | 2012-11-27 | — | — | US | disclosed |
| WO-2011136927-A1 | 3-(4-((1H-IMIDAZOL-1-YL)METHYL)PHENYL)-5-ARYL-1,2,4-OXADIAZOLE DERIVATIVES AS SPHINGOSINE-1 PHOSPHATE RECEPTORS MODULATORS | ALLERGAN, INC. (US) | 2011-11-03 | — | — | WO | disclosed |
| US-20110263661-A1 | 3-(4-((1H-IMIDAZOL-1-YL)METHYL)PHENYL)-5-ARYL-1,2,4-OXADIAZOLE DERIVATIVES AS SPHINGOSINE-1 PHOSPHATE RECEPTORS MODULATORS | ALLERGAN, INC. (US) | 2011-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263661-A1 | 3-(4-((1H-IMIDAZOL-1-YL)METHYL)PHENYL)-5-ARYL-1,2,4-OXADIAZOLE DERIVATIVES AS SPHINGOSINE-1 PHOSPHATE RECEPTORS MODULATORS | S1PR3, S1PR1, S1PR4 | CA12 4827/4885CA1 4670/4885CA2 3830/4885 |
| US-20120302606-A1 | 3-(4-((1H-IMIDAZOL-1-YL)METHYL)PHENYL)-5-ARYL-1,2,4-OXADIAZOLE DERIVATIVES AS SPHINGOSINE-1 PHOSPHATE RECEPTORS MODULATORS | S1PR3, S1PR1, S1PR4 | CA12 4827/4885CA1 4670/4885CA2 3830/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.